Literature DB >> 24973822

The risk of unblinding was infrequently and incompletely reported in 300 randomized clinical trial publications.

Segun Bello1, Helene Moustgaard2, Asbjørn Hróbjartsson2.   

Abstract

OBJECTIVES: To assess the proportion of clinical trials explicitly reporting the risk of unblinding, to evaluate the completeness of reporting on unblinding risk, and to describe the reported procedures involved in assessing unblinding. STUDY DESIGN AND
SETTING: We sampled at random 300 blinded randomized clinical trials indexed in PubMed in 2010. Two authors read the trial publications and extracted data independently.
RESULTS: Twenty-four trial publications, or 8% (95% confidence interval [CI], 5, 12%), explicitly reported the risk of unblinding, of which 16 publications, or 5% (95% CI, 3, 8%), reported compromised blinding; and 8 publications, or 3% (95% CI, 1, 5%), intact blinding. The reporting on risk of unblinding in the 24 trial publications was generally incomplete. The median proportion of assessments per trial affected by unblinding was 3% (range 1-30%). The most common mechanism for unblinding was perceptible physical properties of the treatments, for example, a difference in the taste and odor of a typhoid vaccine compared with its placebo.
CONCLUSION: Published articles on randomized clinical trials infrequently reported risk of unblinding. This may reflect a tendency for avoiding reporting actual or suspected unblinding or a genuine low risk of unblinding.
Copyright © 2014 Elsevier Inc. All rights reserved.

Keywords:  Blinding; Designs; Masking; Methods; Randomized clinical trials; Reporting; Unblinding

Mesh:

Year:  2014        PMID: 24973822     DOI: 10.1016/j.jclinepi.2014.05.007

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  6 in total

1.  Blinded Outcome Assessment Was Infrequently Used and Poorly Reported in Open Trials.

Authors:  Brennan C Kahan; Sunita Rehal; Suzie Cro
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

Review 2.  The matching quality of experimental and control interventions in blinded pharmacological randomised clinical trials: a methodological systematic review.

Authors:  Segun Bello; Maoling Wei; Jørgen Hilden; Asbjørn Hróbjartsson
Journal:  BMC Med Res Methodol       Date:  2016-02-13       Impact factor: 4.615

3.  Low Reporting of Cointerventions in Recent Cardiovascular Clinical Trials: A Systematic Review.

Authors:  Elisavet Moutzouri; Luise Adam; Martin Feller; Lamprini Syrogiannouli; Bruno R Da Costa; Cinzia Del Giovane; Douglas C Bauer; Drahomir Aujesky; Arnaud Chiolero; Nicolas Rodondi
Journal:  J Am Heart Assoc       Date:  2020-06-12       Impact factor: 5.501

4.  Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

Authors:  Huseyin Naci; Courtney Davis; Jelena Savović; Julian P T Higgins; Jonathan A C Sterne; Bishal Gyawali; Xochitl Romo-Sandoval; Nicola Handley; Christopher M Booth
Journal:  BMJ       Date:  2019-09-18

Review 5.  Blinding in Clinical Trials: Seeing the Big Picture.

Authors:  Thomas F Monaghan; Christina W Agudelo; Syed N Rahman; Alan J Wein; Jason M Lazar; Karel Everaert; Roger R Dmochowski
Journal:  Medicina (Kaunas)       Date:  2021-06-24       Impact factor: 2.430

Review 6.  Placebo and Side Effects Confound Clinical Trials on New Antitussives.

Authors:  Ronald Eccles
Journal:  Lung       Date:  2021-07-19       Impact factor: 2.584

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.